DelveInsight’s Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Hepatic Encephalopathy Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Hepatic Encephalopathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hepatic Encephalopathy: Overview
Hepatic encephalopathy is a brain disorder that develops in some individuals with liver disease. It is a complex disorder that encompasses a spectrum or continuum of disease that ranges from a subtle condition with no outward signs or symptoms to a severe form that can cause serious, life-threatening complications. It is manifested by the broad spectrum of neuropsychiatric disturbances such as defects in cognitive, emotional, behavioral, psychomotor, and locomotive functions. This condition is characterized by personality changes, intellectual impairment, and a depressed level of consciousness.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market
Some of the key facts of the Hepatic Encephalopathy Market Report
- DelveInsight’s estimations suggest that the majority of cases of Hepatic Encephalopathy are males as compared to female. There was a total of around 432,631 male and approximately 162,460 female cases of Hepatic Encephalopathy in 2020 in the United States.
- The total number of cases of Hepatic Encephalopathy (HE) in the 7MM was estimated to be approximately 856,610 in 2020.
- In 2020 among EU-5 countries, the United Kingdom had the highest number of cases with approximately 56,099 followed by Germany with approximately 53,878 cases and France with about 44,857 cases. While, Spain has the least number of cases with approximately 18,715.
Hepatic Encephalopathy Market
Hepatic Encephalopathy market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Hepatic Encephalopathy in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Hepatic Encephalopathy market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Hepatic Encephalopathy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Hepatic Encephalopathy Market Outlook
At present, there is only one therapy in the late stage of management, MNK-6105, being developed by Mallinckrodt Pharmaceuticals, for the treatment of hepatic encephalopathy and is expected to launch during the forecast period [2021-2030], and shall create a significant impact on treatment market for this indication. During the forecast period, the share of the current therapies will decrease due to the expected launch of emerging therapies, as the patient will likely shift to the newer therapies.
Management of overt HE includes treating patients with acute HE episodes, preventing HE recurrence, and identifying and managing precipitating factors associated with the development of HE. The two main forms of medical therapy for HE are non-absorbable disaccharides (i.e., lactitol and lactulose) and non-absorbable antibiotics (i.e. rifaximin). The hyperammonemia and inflammation that occurs due to urea breakdown in cirrhotics have led to the development of HE treatments that target gut bacteria. Treatments for OHE approved by the US Food and Drug Administration (FDA), as well as some unapproved treatments, are available for use. It is important to remember that in patients with cirrhosis and portosystemic shunting, skeletal muscle mass and renal clearance are vital to neurotoxin clearance. Nutrition may also play a key role in managing HE and preventing a recurrence. The second line, less accepted therapies, include probiotics, branched-chain amino acids (BCAAs), flumazenil, zinc, and ammonia scavengers.
Hepatic Encephalopathy Epidemiology
The epidemiology section covers insights about the historical and current Hepatic Encephalopathy patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hepatic Encephalopathy Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatic Encephalopathy market or expected to get launched in the market during the study period. The analysis covers Hepatic Encephalopathy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Hepatic Encephalopathy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Hepatic Encephalopathy Market Size
The expected launch of emerging therapies, during the forecast period (2021-2030) will contribute to an increase in the market size of Hepatic Encephalopathy.
Hepatic Encephalopathy Companies includes-
- Salix Pharmaceuticals
- Bausch Health
- Axcella Health, Inc.
- Umecrine Cognition
- Vedanta Biosciences
- Patricia Bloom
- Rebiotix, and others
Hepatic Encephalopathy Therapies includes-
- MNK-6105/ MNK-6106
- Golexanolone (GR3207), and others
View Detailed Report of key players and therapies @ https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market
Table of content
- Key Insights
- Executive Summary
- Competitive Intelligence Analysis
- Market Overview at a Glance
- Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Hepatic Encephalopathy Treatment
- Marketed Products
- Emerging Therapies
- Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview
- KOL Views
- Market Drivers
- Market Barriers
- DelveInsight Capabilities
- About DelveInsight
DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States